PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Antibody drug conjugates (ADCs) have become an important modality of clinical cancer treatment. However, traditional ADCs have some limitations, such as reduced permeability in solid tumors due to the high molecular weight of monoclonal antibodies, difficulty in preparation and heterogeneity of prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qiyu, Li, Wenjing, Xu, Keyuan, Xing, Yutong, Shi, Haobo, Jing, Zhe, Li, Shuang, Hong, Zhangyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913616/
https://www.ncbi.nlm.nih.gov/pubmed/33546481
http://dx.doi.org/10.3390/ijms22041540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913616/
https://www.ncbi.nlm.nih.gov/pubmed/33546481
http://dx.doi.org/10.3390/ijms22041540

Ejemplares similares